ACETAMINOPHEN AND PHENYLEPHRINE HYDROCHLORIDE and INAPPROPRIATE SCHEDULE OF PRODUCT ADMINISTRATION

Overview

INAPPROPRIATE SCHEDULE OF PRODUCT ADMINISTRATION is the #6 most commonly reported adverse reaction for ACETAMINOPHEN AND PHENYLEPHRINE HYDROCHLORIDE, manufactured by Kenvue Brands LLC. There are 2 FDA adverse event reports linking ACETAMINOPHEN AND PHENYLEPHRINE HYDROCHLORIDE to INAPPROPRIATE SCHEDULE OF PRODUCT ADMINISTRATION. This represents approximately 3.9% of all 51 adverse event reports for this drug.

Patients taking ACETAMINOPHEN AND PHENYLEPHRINE HYDROCHLORIDE who experience inappropriate schedule of product administration should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.

Reporting Frequency

INAPPROPRIATE SCHEDULE OF PRODUCT ADMINISTRATION is moderately reported among ACETAMINOPHEN AND PHENYLEPHRINE HYDROCHLORIDE users, representing a notable but not dominant share of adverse events.

Other Side Effects of ACETAMINOPHEN AND PHENYLEPHRINE HYDROCHLORIDE

In addition to inappropriate schedule of product administration, the following adverse reactions have been reported for ACETAMINOPHEN AND PHENYLEPHRINE HYDROCHLORIDE:

• FOETAL EXPOSURE DURING PREGNANCY — 4 reports
• INCORRECT DOSE ADMINISTERED — 4 reports
• AUTISM SPECTRUM DISORDER — 2 reports
• BLOOD PRESSURE INCREASED — 2 reports
• HEADACHE — 2 reports
• OFF LABEL USE — 2 reports
• PRODUCT USE IN UNAPPROVED INDICATION — 2 reports
• BLOOD URINE PRESENT — 1 reports
• CARDIAC ARREST — 1 reports
• CEREBROVASCULAR ACCIDENT — 1 reports

Other Drugs Associated with INAPPROPRIATE SCHEDULE OF PRODUCT ADMINISTRATION

The following drugs have also been linked to inappropriate schedule of product administration in FDA adverse event reports:

Does ACETAMINOPHEN AND PHENYLEPHRINE HYDROCHLORIDE cause INAPPROPRIATE SCHEDULE OF PRODUCT ADMINISTRATION?

INAPPROPRIATE SCHEDULE OF PRODUCT ADMINISTRATION has been reported as an adverse event in 2 FDA reports for ACETAMINOPHEN AND PHENYLEPHRINE HYDROCHLORIDE. This does not prove causation, but indicates an association observed in post-market surveillance data.

How common is INAPPROPRIATE SCHEDULE OF PRODUCT ADMINISTRATION with ACETAMINOPHEN AND PHENYLEPHRINE HYDROCHLORIDE?

INAPPROPRIATE SCHEDULE OF PRODUCT ADMINISTRATION accounts for approximately 3.9% of all adverse event reports for ACETAMINOPHEN AND PHENYLEPHRINE HYDROCHLORIDE, making it a notable side effect.

What should I do if I experience INAPPROPRIATE SCHEDULE OF PRODUCT ADMINISTRATION while taking ACETAMINOPHEN AND PHENYLEPHRINE HYDROCHLORIDE?

If you experience inappropriate schedule of product administration while taking ACETAMINOPHEN AND PHENYLEPHRINE HYDROCHLORIDE, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.

Related Pages